Literature DB >> 7513631

Hepatitis C infection in potential recipients with normal liver biochemistry does not preclude renal transplantation.

S Kazi1, S Prasad, R Pollak, T Holzer, C Heynen, A J Fabrega, D Pitrak, T J Layden.   

Abstract

The hepatitis C virus (HCV) may be an important cause of chronic liver disease in renal transplant recipients. We investigated retrospectively the incidence and outcome of HCV infection in long-term renal transplant recipients and patients on hemodialysis. Stored, pretransplant sera of transplant recipients with normal liver biochemistry at surgery were tested for hepatitis C by a second-generation enzyme immunoassay. Hemodialysis patients were tested by a first-generation enzyme-linked immunosorbent assay (ELISA) against c100-3. We studied 252 renal transplant recipients and 58 hemodialysis patients followed for 65 +/- 10 months and 26 +/- 6 months, respectively. Fifteen percent (38/252) of the transplant recipients were HCV positive as were 3/58 (5%) of the hemodialysis patients. Overt liver disease occurred in 22/252 (8.7%) transplant recipients and none in the hemodialysis group. Thirty-six percent (8/22) of transplant recipients with overt liver disease were HCV positive. No HCV-positive patients died of liver failure. Of six biopsies in the HCV-positive transplant group, two had histological evidence of CAH. CAH was seen in six of eight biopsies in the HCV-negative transplants and two of these latter patients progressed to cirrhosis. No hemodialysis patients had clinical or histological evidence of chronic liver disease. Two HCV-negative transplant patients died of liver failure, while no deaths related to liver disease occurred in hemodialysis patients regardless of HCV status. We conclude that hepatitis C may cause chronic hepatitis in renal transplant patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513631     DOI: 10.1007/bf02087544

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Hepatitis C virus infection in kidney transplant patients.

Authors:  R Marcen; J Pascual; L Orofino; R Fernandez Muñoz; J L Teruel; M L Celma; F Liaño; J Ortuño
Journal:  Transplant Proc       Date:  1992-02       Impact factor: 1.066

2.  Spectrum of liver disease in renal transplant recipients.

Authors:  A J Ware; J P Luby; E H Eigenbrodt; D L Long; A R Hull
Journal:  Gastroenterology       Date:  1975-04       Impact factor: 22.682

3.  Hepatitis C virus infection among kidney transplant recipients.

Authors:  E Ponz; J M Campistol; M Bruguera; J M Barrera; C Gil; J B Pinto; J Andreu
Journal:  Kidney Int       Date:  1991-10       Impact factor: 10.612

4.  Herpesviruses in renal transplant patients.

Authors:  F D Pien; T F Smith; C F Anderson; M L Webel; H F Taswell
Journal:  Transplantation       Date:  1973-11       Impact factor: 4.939

5.  Cytomegalovirus syndrome following renal transplantation.

Authors:  R N Fine; C M Grushkin; M Malekzadeh; H T Wright
Journal:  Arch Surg       Date:  1972-10

6.  Detection of antibody to hepatitis C virus in renal transplant recipients.

Authors:  D Roth; J A Fernandez; G W Burke; V Esquenazi; J Miller
Journal:  Transplantation       Date:  1991-02       Impact factor: 4.939

7.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy.

Authors:  J H Hoofnagle; G M Dusheiko; D F Schafer; E A Jones; K C Micetich; R C Young; J Costa
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

8.  Intrahepatic cholestasis due to azathioprine.

Authors:  M Sparberg; N Simon; F del Greco
Journal:  Gastroenterology       Date:  1969-10       Impact factor: 22.682

9.  Nonhepatitis B-associated liver disease in a renal transplant population.

Authors:  N W Boyce; S R Holdsworth; D Hooke; N M Thomson; R C Atkins
Journal:  Am J Kidney Dis       Date:  1988-04       Impact factor: 8.860

10.  Hepatitis C--its prevalence in end-stage renal failure patients and clinical course after kidney transplantation.

Authors:  C A Stempel; J Lake; G Kuo; F Vincenti
Journal:  Transplantation       Date:  1993-02       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.